BB&T Corp reduced its position in Pfizer, Inc. (NYSE:PFE) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,029,651 shares of the biopharmaceutical company’s stock after selling 23,380 shares during the period. Pfizer makes up approximately 0.7% of BB&T Corp’s portfolio, making the stock its 26th largest position. BB&T Corp owned about 0.06% of Pfizer worth $34,586,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. increased its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. increased its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. increased its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer during the first quarter worth about $121,000. Finally, Cable Hill Partners LLC increased its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.
Pfizer, Inc. (NYSE PFE) traded up 0.43% on Monday, hitting $32.81. 5,677,401 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $33.30 and its 200-day moving average price is $33.38. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The company has a market cap of $195.13 billion, a PE ratio of 24.00 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 EPS. Analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.92%. Pfizer’s payout ratio is currently 94.12%.
A number of research firms have recently issued reports on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research note on Thursday, April 27th. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price objective on shares of Pfizer in a research note on Monday, April 24th. Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $36.00 in a research note on Thursday, July 20th. Finally, Barclays PLC reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and a consensus target price of $37.61.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.